Drug Interactions between Detrol and mobocertinib

Consumer information for this interaction is not currently available.

GENERALLY AVOID: Mobocertinib can cause concentration-dependent, life-threatening prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In a subset of 250 patients who had electrocardiograms (ECGs) during clinical studies with mobocertinib 160 mg orally once daily, 1.2% of patients had a QTc interval greater than 500 msec and 11% of patients had a change-from-baseline QTc interval greater than 60 msec. Torsades de pointes occurred in 1 patient (0.4%). Clinical trials of mobocertinib did not include patients with baseline QTc greater than 470 msec. From cardiac electrophysiology studies, the largest mean increase in QTc was 23.0 msec following administration of mobocertinib 160 mg once daily. In general, the risk of an individual agent or a combination of agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances (e.g., hypokalemia, hypomagnesemia). In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).

MANAGEMENT: Avoid use of mobocertinib with concomitant drugs which are known to prolong the QT interval. If concomitant use is unavoidable, monitor the QTc interval more frequently with ECGs.